Patents by Inventor Sharon Pokropinski

Sharon Pokropinski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240117025
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Application
    Filed: November 13, 2023
    Publication date: April 11, 2024
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
  • Patent number: 11851481
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: December 26, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
  • Publication number: 20210101967
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 8, 2021
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
  • Publication number: 20190055307
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Application
    Filed: October 19, 2018
    Publication date: February 21, 2019
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
  • Patent number: 10144776
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: December 4, 2018
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: William H. Frey, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa
  • Publication number: 20170044244
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Inventors: William H. Frey, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa
  • Patent number: 9556260
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: January 31, 2017
    Assignees: Baxalta Incorporated, Balxalta GmbH
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
  • Publication number: 20140242067
    Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.
    Type: Application
    Filed: February 25, 2014
    Publication date: August 28, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: William H. Frey, II, Leah Ranae Bresin Hanson, Sharon Pokropinski, Francisco M. Rausa, III
  • Publication number: 20130052188
    Abstract: The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor.
    Type: Application
    Filed: September 14, 2012
    Publication date: February 28, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Kyungyoon Min, Larry Backes, Francisco M. Rausa, III, Shawn F. Bairstow, Sindhu Ramachandran, Sharon Pokropinski
  • Publication number: 20130011387
    Abstract: The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 10, 2013
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Kyungyoon Min, Larry Backes, Francisco M. Rausa, III, Shawn F. Bairstow, Sindhu Ramachandran, Sharon Pokropinski
  • Publication number: 20120230872
    Abstract: The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor.
    Type: Application
    Filed: April 11, 2012
    Publication date: September 13, 2012
    Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
    Inventors: Kyungyoon Min, Larry Backes, Francisco M. Rausa, III, Shawn F. Bairstow, Sindhu Ramachandran, Sharon Pokropinski
  • Publication number: 20100158893
    Abstract: The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor.
    Type: Application
    Filed: December 19, 2008
    Publication date: June 24, 2010
    Applicants: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Kyungyoon Min, Larry Backes, Francisco M. Rausa, III, Shawn F. Bairstow, Sindhu Ramachandran, Sharon Pokropinski
  • Patent number: 5510115
    Abstract: An anhydrous solid water-soluble composition and method for direct controlled administration of beneficial agents to a flowing medical fluid. The beneficial agents are geometrically dispersed in a solid matrix and isolated from one and other to allow administration of mutually reactive agents.
    Type: Grant
    Filed: December 8, 1994
    Date of Patent: April 23, 1996
    Assignee: Baxter Travenol Laboratories, Inc.
    Inventors: Julian P. Breillatt, Jr., Lecon Woo, Deanna J. Nelson, Richard Appl, Naomi L. Weinless, Sharon Pokropinski, Paul Soltys, Sumner A. Barenberg